GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » EV-to-EBIT
中文

Enzon Pharmaceuticals (Enzon Pharmaceuticals) EV-to-EBIT : 39.49 (As of Apr. 25, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Enzon Pharmaceuticals's Enterprise Value is $-41.23 Mil. Enzon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.04 Mil. Therefore, Enzon Pharmaceuticals's EV-to-EBIT for today is 39.49.

The historical rank and industry rank for Enzon Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

ENZN' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.35   Med: 0.95   Max: 63.13
Current: 39.49

During the past 13 years, the highest EV-to-EBIT of Enzon Pharmaceuticals was 63.13. The lowest was -26.35. And the median was 0.95.

ENZN's EV-to-EBIT is ranked worse than
82.88% of 444 companies
in the Biotechnology industry
Industry Median: 8.185 vs ENZN: 39.49

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Enzon Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $-40.07 Mil. Enzon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.04 Mil. Enzon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.61%.


Enzon Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Enzon Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals EV-to-EBIT Chart

Enzon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.76 -8.24 47.38 27.79 38.38

Enzon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.79 26.06 30.23 34.33 38.38

Competitive Comparison of Enzon Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Enzon Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's EV-to-EBIT falls into.



Enzon Pharmaceuticals EV-to-EBIT Calculation

Enzon Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-41.225/-1.044
=39.49

Enzon Pharmaceuticals's current Enterprise Value is $-41.23 Mil.
Enzon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzon Pharmaceuticals  (OTCPK:ENZN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Enzon Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-1.044/-40.06922417
=2.61 %

Enzon Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $-40.07 Mil.
Enzon Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enzon Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Headlines